Abstract: A controller is provided that is configured to perform: obtaining information about a condition for an image that is provided to a user, and that corresponds to a preference of the user; specifying at least one predetermined position at which an image satisfying the condition can be taken; and generating a command for a moving object to move to the predetermined position and to take an image, and transmitting the command to the moving object.

Abstract: A substrate processing apparatus includes a device management controller including a parts management control part configured to monitor the state of parts constituting the apparatus, a device state monitoring control part configured to monitor integrity of device data obtained from an operation state of the parts constituting the apparatus, and a data matching control part configured to monitor facility data provided from a factory facility to the apparatus. The device management controller is configured to derive information evaluating the operation state of the apparatus based on a plurality of monitoring result data selected from a group consisting of maintenance timing monitoring result data acquired by the parts management control part, device state monitoring result data acquired by the device state monitoring control part, and utility monitoring result data acquired by the data matching control part.

Abstract: In an embodiment, an object of the present invention is to provide a double-stranded nucleic acid complex having a novel structure. In an embodiment, the present invention relates to a nucleic acid complex comprising a first nucleic acid strand and a second nucleic acid strand, wherein said first nucleic acid strand: (1) is capable of hybridizing to at least a part of a target transcriptional product; (2) has an antisense effect on the target transcriptional product; and (3) is a gapmer comprising a central region, and a 5? wing region and a 3? wing region, said second nucleic acid strand comprises at least one sugar-unmodified central region (first exposed region) consisting of one sugar-unmodified ribonucleoside or two or three contiguous sugar-unmodified ribonucleosides linked by an internucleoside bond, which is or are complementary to a part of said first nucleic acid strand, and said first nucleic acid strand is annealed to said second nucleic acid strand.

Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

Abstract: A test device having a micro flow channel including a reaction part where a reactant that is reactive to a tested chemical dispersed in a tested fluid is fixed, and at least one actuator for actuating the tested fluid to move in at least one of two opposite sides of the micro flow channel so as to homogenize a density distribution of the tested chemical in the tested fluid. The tested fluid is sent in the micro flow channel a plurality of times.

Abstract: The object of the present invention is to provide a nucleic acid agent that can be efficiently delivered to the nervous system, particularly the central nervous system to which the BBB mechanism prevents drug delivery, and can produce an antisense effect on a target transcriptional product at the delivered site, and a composition comprising the same. Provided is a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand capable of hybridizing to part of a target transcriptional product, and has an antisense effect on the target transcriptional product, to a second nucleic acid strand comprising a base sequence complementary to the first nucleic acid strand, and is bound to tocopherol or an analog thereof, cholesterol or an analog thereof, or a substituted or unsubstituted C1-30 alkyl group, a substituted or unsubstituted C2-30 alkenyl group, or a substituted or unsubstituted C1-30 alkoxy group.

Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.

Abstract: A power tool (1) includes an electric motor (2) as a drive source and a start switch (20; 61) that starts the electric motor (2) and is lockable in an ON position in a lock-ON state. An electromagnetic actuator (30; 40; 50; 60) pushes out or pulls in an actuation pin (30a; 40a; 50a; 60a) with respect to a body of the electromagnetic actuator (30; 40; 50; 60) in response to cutting off of a supply of electrical current to the power tool (1). The pushed-out or pulled-in actuation pin, directly or indirectly, disengages the start switch (20; 61) from the lock-ON state and/or prevents the start switch (20; 61) from being shifted into the lock-ON state.

Abstract: [Problem to be solved] The present invention provides an antibody-drug conjugate (ADC). The present invention also provides a conjugate of an anti-CD71 antibody or an antigen-binding fragment thereof with a drug. The present invention further provides a conjugate of Fab? with a drug. The present invention further provides a composition comprising the conjugate for delivering the drug to a tissue or a cell of muscle or the like. [Solution] A conjugate of an anti-CD71 antibody or an antigen-binding fragment thereof with a drug, and a conjugate of Fab? of an antibody with a drug.

Abstract: In a rack and pinion mechanism 80, a driving-side pinion gear 83 and a driven-side pinion gear 86 are provided to be coaxially rotatable relative to each other within a predetermined angle range. Because of this construction, in a case where a time when a driver 3 reaches an advancing end position and contacts an advancing end damper 19 deviates from a time when a weight device 5 reaches a retracting end position and contacts a moving end damper 7, an excessive external force is not applied to engaging teeth 81a and 82a by relative rotation of the pinion gears 83 and 86. Thus, due to this construction, durability of the rack and pinion mechanism 80, where end impacts are absorbed through elastic deformation, is improved.

Abstract: An air compressor includes an internal combustion engine for driving an air compressing part that generates compressed air, which is stored in an air-storage tank. At a point in time when the air pressure inside the air-storage tank has increased to a first set pressure, the supply of fuel to the engine is cut off, thereby stopping the engine and the combustion of fuel. At a point in time when the air pressure inside the air-storage tank has decreased from the first set pressure to a second set pressure, a starter motor is started up to resume the operation of the engine.

Abstract: In a rack and pinion mechanism 80, a driving-side pinion gear 83 and a driven-side pinion gear 86 are provided to be coaxially rotatable relative to each other within a predetermined angle range. Because of this construction, in a case where a time when a driver 3 reaches an advancing end position and contacts an advancing end damper 19 deviates from a time when a weight device 5 reaches a retracting end position and contacts a moving end damper 7, an excessive external force is not applied to engaging teeth 81a and 82a by relative rotation of the pinion gears 83 and 86. Thus, due to this construction, durability of the rack and pinion mechanism 80, where end impacts are absorbed through elastic deformation, is improved.

Abstract: A power tool (1) includes an electric motor (2) as a drive source and a start switch (20; 61) that starts the electric motor (2) and is lockable in an ON position in a lock-ON state. An electromagnetic actuator (30; 40; 50; 60) pushes out or pulls in an actuation pin (30a; 40a; 50a; 60a) with respect to a body of the electromagnetic actuator (30; 40; 50; 60) in response to cutting off of a supply of electrical current to the power tool (1). The pushed-out or pulled-in actuation pin, directly or indirectly, disengages the start switch (20; 61) from the lock-ON state and/or prevents the start switch (20; 61) from being shifted into the lock-ON state.

Abstract: This invention provides an injectable formulation to be administered intramuscularly or subcutaneously that is used for the prevention or treatment of polycystic kidney disease, and that can maintain a therapeutically effective blood concentration of tolvaptan for a long period of time; and a process for producing the same. More specifically, this invention relates to an injectable depot formulation comprising (1) a particle containing optically active tolvaptan as an active ingredient and (2) a pharmaceutically acceptable carrier for injection, and a process for producing the same.

Abstract: A surface plasmon resonance fluorescence analysis device emits a light beam to a prism in which a metal film is formed on a prescribed surface while changing an angle of incidence relative to the metal film in a state in which the light beam is totally reflected, measures light generated on a surface of the metal film, determines an angle at which the light beam enters the metal film based on a change in intensity of the measured light, adjusts the emitting direction of the light beam so that the light beam enters the metal film at the determined angle of incidence, and measures fluorescence generated on the surface of the metal film in a state in which the light beam is emitted the adjusted direction.

Abstract: An air compressor includes an internal combustion engine for driving an air compressing part that generates compressed air, which is stored in an air-storage tank. At a point in time when the air pressure inside the air-storage tank has increased to a first set pressure, the supply of fuel to the engine is cut off, thereby stopping the engine and the combustion of fuel. At a point in time when the air pressure inside the air-storage tank has decreased from the first set pressure to a second set pressure, a starter motor is started up to resume the operation of the engine.

Abstract: This invention provides an injectable formulation to be administered intramuscularly or subcutaneously that is used for the prevention or treatment of polycystic kidney disease, and that can maintain a therapeutically effective blood concentration of tolvaptan for a long period of time; and a process for producing the same. More specifically, this invention relates to an injectable depot formulation comprising (1) a particle containing optically active tolvaptan as an active ingredient and (2) a pharmaceutically acceptable carrier for injection, and a process for producing the same.

Abstract: There are provided a micro mixer capable of efficiently mixing at least two types of liquids in a simple structure and a microfluidic chip provided with the micro mixer. In order to achieve the object, the micro mixer includes a minute passage through which first and second liquids are caused to flow respectively, and a mixing vessel in which a liquid injecting port caused to communicate with the minute passage is provided in a bottom part, and the liquid injecting port is provided in a shifted position from a center of the bottom part in the bottom part. Moreover, the liquid injecting port may be provided in a shifted position from a center line of the mixing vessel.

Abstract: A test device having a micro flow channel including a reaction part where a reactant that is reactive to a tested chemical dispersed in a tested fluid is fixed, and at least one actuator for actuating the tested fluid to move in at least one of two opposite sides of the micro flow channel so as to homogenize a density distribution of the tested chemical in the tested fluid. The tested fluid is sent in the micro flow channel a plurality of times.